12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Truvada emtricitabine/tenofovir infectious data

Researchers at Stanford University reported data from a cost-effectiveness analysis showing that pre-exposure prophylaxis (PrEP) with Truvada could prevent a substantial number of new HIV infections among the general population of men who have sex with men, but that its use would be expensive. Specifically, the researchers said initiating PrEP in all U.S. men ages 13-64 who have sex with men would reduce the incidence of new HIV infections by 51% over 20 years vs. no PrEP, but at an ICER of $216,480 per QALY gained. Additionally, initiating PrEP in 20% of the population of U.S. men who have sex with men would reduce...

Read the full 499 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >